Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Long-Term Investments (2020 - 2024)

ADC Therapeutics has reported Long-Term Investments over the past 5 years, most recently at $260000.0 for Q2 2024.

  • Quarterly results put Long-Term Investments at $260000.0 for Q2 2024, down 99.08% from a year ago — trailing twelve months through Jun 2024 was $260000.0 (down 99.08% YoY), and the annual figure for FY2023 was $1.6 million, down 78.37%.
  • Long-Term Investments reached $260000.0 in Q2 2024 per ADCT's latest filing, down from $930000.0 in the prior quarter.
  • Across five years, Long-Term Investments topped out at $47.9 million in Q4 2020 and bottomed at $260000.0 in Q2 2024.
  • Median Long-Term Investments over the past 5 years was $29.5 million (2023), compared with a mean of $27.2 million.
  • The largest annual shift saw Long-Term Investments fell 18.25% in 2022 before it tumbled 99.08% in 2024.
  • Over 5 years, Long-Term Investments stood at $47.9 million in 2020, then plummeted by 63.06% to $17.7 million in 2021, then crashed by 56.98% to $7.6 million in 2022, then plummeted by 78.37% to $1.6 million in 2023, then tumbled by 84.21% to $260000.0 in 2024.
  • Business Quant data shows Long-Term Investments for ADCT at $260000.0 in Q2 2024, $930000.0 in Q1 2024, and $1.6 million in Q4 2023.